{"disease":{"id":"gaucher-disease-type-i","name":"gaucher disease type i"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05687474","title":"Baby Detect : Genomic Newborn Screening","phase":"","overall_status":"COMPLETED","enrollment_count":6824,"lead_sponsor_name":"Centre Hospitalier Universitaire de Liege","has_results":false},{"nct_id":"NCT03240653","title":"Gaucherite - A Study to Stratify Gaucher Disease","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Cambridge University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT04470713","title":"Natural History Study for Pediatric Patients With Early Onset of Either GM1 Gangliosidosis, GM2 Gangliosidoses, or Gaucher Disease Type 2","phase":"","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Idorsia Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT03485677","title":"Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":57,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05222906","title":"Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT05447494","title":"Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"CANbridge (Suzhou) Bio-pharma Co., Ltd.","has_results":false},{"nct_id":"NCT03746587","title":"Study of Arimoclomol in Patients Diagnosed With Gaucher Disease Type 1 or 3","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":39,"lead_sponsor_name":"ZevraDenmark","has_results":false},{"nct_id":"NCT00433147","title":"A Study of AT2101 (Afegostat Tartrate) in Adult Patients With Type 1 Gaucher Disease Currently Receiving Enzyme Replacement Therapy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT03333447","title":"Retrospective and Prospective Observational Study of MRI Changes in Bone and Visceral Lesions of Patients With Type 1 Gaucher Disease Treated With VPRIV® (Velaglucerase Alfa)","phase":"","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"CEN Biotech","has_results":false},{"nct_id":"NCT00446550","title":"A Study of Oral AT2101 (Afegostat Tartrate) in Treatment-naive Patients With Gaucher Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":19,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT02843035","title":"Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":12,"lead_sponsor_name":"Genzyme, a Sanofi Company","has_results":false},{"nct_id":"NCT04532047","title":"PEARL (PrEnAtal Enzyme Replacement Therapy for Lysosomal Storage Disorders)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06143904","title":"A Study to Evaluate Absolute Bioavailability, Absorption, Metabolism, and Excretion of Genz-112638 in Healthy Male Participants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT00813865","title":"A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Amicus Therapeutics","has_results":true},{"nct_id":"NCT03519646","title":"Eliglustat on Gaucher Disease Type IIIB","phase":"NA","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"National Taiwan University Hospital","has_results":false},{"nct_id":"NCT06162338","title":"A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I","phase":"NA","overall_status":"RECRUITING","enrollment_count":3,"lead_sponsor_name":"He Huang","has_results":false},{"nct_id":"NCT04189601","title":"Complement Activation in the Lysosomal Storage Disorders","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Melbourne Health","has_results":false}],"total":17},"guidelines":[],"source":"Drug Landscape verified database"}